James J. Mulé, IPh.D. has served as a member of our board of directors since 2018. Dr. Mulé has served as Associate Center Director for Translational Science and the Michael McGillicuddy (U.S. Senator Connie Mack (ret.) & Family) Endowed Chair for Melanoma Research and Treatment since 2003 and is the Associate Center Director of the Moffitt Cancer Center, Tampa, Florida, where he has served as a Director since 2003. Since 1993, Dr. Mulé has served multiple tenures as a special government employee to the FDA at the Center for Drug Evaluation and Research and at the Center for Biologics Evaluation and Research and to the National Cancer Institute (NCI). Dr. Mulé also served on the board of directors of publicly traded company Fulgent Genetics from 2016 to 2020. Dr. Mulé serves on the advisory boards of numerous biotechnology companies, pharmaceutical companies, NCI-designated cancer centers and investment funds, including Buffett Cancer Center, Omaha; Masonic Cancer Center, Minneapolis; Affyimmune Therapeutics; Aleta Biotherapeutics; OncoPep; Turnstone Biologics; UbiVac; Vault Pharma; Vycellix; and Noble Life Science Partners. Dr. Mulé holds an Interdisciplinary Ph.D. in Tumor Immunology, Immunocytology, and Immunopathology from the University of Washington and the Fred Hutchinson Cancer Research Center, Seattle, Washington, a M.S. in Cellular Immunology from the University of Washington School of Medicine and a B.A. from New Jersey City University. Dr. Mulé received his formal postgraduate training at the Surgery Branch, Division of Cancer Treatment, NCI, National Institutes of Health (NIH), Bethesda, Maryland. Dr. Mulé has held tenured senior positions at the NCI/NIH and the University of Michigan, Ann Arbor. Dr. Mulé’s extensive regulatory, basic, translational and clinical research as well as administration leadership experience in both non-profit and for-profit entities and the biopharmaceutical industry contributed to our board of directors’ conclusion that he should serve as a director of our company.
What is James Mulay's net worth?
The estimated net worth of James Mulay is at least $1.70 million as of July 10th, 2026. Mulay owns 24,165 shares of CG Oncology stock worth more than $1,696,141 as of July 20th. This net worth approximation does not reflect any other investments that Mulay may own. Learn More about James Mulay's net worth.
How do I contact James Mulay?
Has James Mulay been buying or selling shares of CG Oncology?
During the past quarter, James Mulay has sold $1,816,241.40 in shares of CG Oncology stock. Most recently, James Mulay sold 24,165 shares of the business's stock in a transaction on Friday, July 10th. The shares were sold at an average price of $75.16, for a transaction totalling $1,816,241.40. Following the completion of the sale, the director now directly owns 24,165 shares of the company's stock, valued at $1,816,241.40. Learn More on James Mulay's trading history.
Who are CG Oncology's active insiders?
Are insiders buying or selling shares of CG Oncology?
In the last year, CG Oncology insiders bought shares 2 times. They purchased a total of 1,886,236 shares worth more than $74,814,436.95. In the last year, insiders at the sold shares 17 times. They sold a total of 241,197 shares worth more than $10,065,478.98. The most recent insider tranaction occured on July, 10th when Director James Mulay sold 24,165 shares worth more than $1,816,241.40. Insiders at CG Oncology own 4.8% of the company.
Learn More about insider trades at CG Oncology. Information on this page was last updated on 7/10/2026.
